(Medical Xpress)—A particular kind of genetic interaction called synthetic dosage lethality (SDL) is a promising avenue for future cancer treatment, according to a study reported in the Proceedings of the National Academy of Sciences. An international group of researchers has designed a network model of these interactions that points toward therapeutic approaches to tumors while also illuminating the value of model-based studies of metabolic processes.
↧